Different Mutator Phenotypes in Mlh1- Versus Pms2-deficient Mice

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1999 Jun 9

PMID 10359802

Citations 39

Authors

X Yao

A B Buermeyer

L Narayanan

D Tran

S M Baker

T A Prolla

P M Glazer

R M Liskay

N Arnheim

Affiliations

Soon will be listed here.

Abstract

Deficiencies in DNA mismatch repair (MMR) result in increased mutation rates and cancer risk in both humans and mice. Mouse strains homozygous for knockouts of either the Pms2 or Mlh1 MMR gene develop cancer but exhibit very different tumor spectra; only Mlh1(-/-) animals develop intestinal tumors. We carried out a detailed study of the microsatellite mutation spectra in each knockout strain. Five mononucleotide repeat tracts at four different chromosomal locations were studied by using single-molecule PCR or an in vivo forward mutation assay. Three dinucleotide repeat loci also were examined. Surprisingly, the mononucleotide repeat mutation frequency in Mlh1(-/-) mice was 2- to 3-fold higher than in Pms2(-/-) animals. The higher mutation frequency in Mlh1(-/-) mice may be a consequence of some residual DNA repair capacity in the Pms2(-/-) animals. Relevant to this idea, we observed that Pms2(-/-) mice exhibit almost normal levels of Mlh1p, whereas Mlh1(-/-) animals lack both Mlh1p and Pms2p. Comparison between Mlh1(-/-) animals and Mlh1(-/-) and Pms2(-/-) double knockout mice revealed little difference in mutator phenotype, suggesting that Mlh1 nullizygosity is sufficient to inactivate MMR completely. The findings may provide a basis for understanding the greater predisposition to intestinal cancer of Mlh1(-/-) mice. Small differences (2- to 3-fold) in mononucleotide repeat mutation rates may have dramatic effects on tumor development, requiring multiple genetic alterations in coding regions. Alternatively, this strain difference in tumor spectra also may be related to the consequences of the absence of Pms2p compared with the absence of both Pms2p and Mlh1p on as yet little understood cellular processes.

Citing Articles

Altered dNTP pools accelerate tumor formation in mice.

Tran P, Mishra P, Williams L, Moskalenko R, Sharma S, Nilsson A Nucleic Acids Res. 2024; 52(20):12475-12486.

PMID: 39360631 PMC: 11551754. DOI: 10.1093/nar/gkae843.

All three MutL complexes are required for repeat expansion in a human stem cell model of CAG-repeat expansion mediated glutaminase deficiency.

Hayward B, Kumari D, Santra S, van Karnebeek C, van Kuilenburg A, Usdin K Sci Rep. 2024; 14(1):13772.

PMID: 38877099 PMC: 11178883. DOI: 10.1038/s41598-024-64480-z.

Efficient prime editing in two-cell mouse embryos using PEmbryo.

Kim-Yip R, McNulty R, Joyce B, Mollica A, Chen P, Ravisankar P Nat Biotechnol. 2024; 42(12):1822-1830.

PMID: 38321114 PMC: 11631759. DOI: 10.1038/s41587-023-02106-x.

All three MutL complexes are required for repeat expansion in a human stem cell model of CAG-repeat expansion mediated glutaminase deficiency.

Hayward B, Kumari D, Santra S, van Karnebeek C, van Kuilenburg A, Usdin K bioRxiv. 2024; .

PMID: 38260514 PMC: 10802475. DOI: 10.1101/2023.12.26.573357.

Genetically engineered mouse models for hereditary cancer syndromes.

Biswas K, Mohammed A, Sharan S, Shoemaker R Cancer Sci. 2023; 114(5):1800-1815.

PMID: 36715493 PMC: 10154891. DOI: 10.1111/cas.15737.

References

Edelmann W, Yang K, Umar A, HEYER J, Lau K, Fan K . Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell. 1997; 91(4):467-77. DOI: 10.1016/s0092-8674(00)80433-x. View

Yamamoto H, Sawai H, Weber T, Rodriguez-Bigas M, Perucho M . Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res. 1998; 58(5):997-1003. View

Prolla T, Baker S, Harris A, Tsao J, Yao X, Bronner C . Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet. 1998; 18(3):276-9. DOI: 10.1038/ng0398-276. View

Baker S, Harris A, Tsao J, Flath T, Bronner C, Gordon M . Enhanced intestinal adenomatous polyp formation in Pms2-/-;Min mice. Cancer Res. 1998; 58(6):1087-9. View

Fink D, Aebi S, Howell S . The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998; 4(1):1-6. View

Flores-Rozas H, Kolodner R . The Saccharomyces cerevisiae MLH3 gene functions in MSH3-dependent suppression of frameshift mutations. Proc Natl Acad Sci U S A. 1998; 95(21):12404-9. PMC: 22844. DOI: 10.1073/pnas.95.21.12404. View

Lengauer C, Kinzler K, Vogelstein B . Genetic instabilities in human cancers. Nature. 1999; 396(6712):643-9. DOI: 10.1038/25292. View

Brown R, Hirst G, Gallagher W, McIlwrath A, Margison G, van der Zee A . hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997; 15(1):45-52. DOI: 10.1038/sj.onc.1201167. View

Nowell P . The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-8. DOI: 10.1126/science.959840. View

10.

Glazer P, Sarkar S, Summers W . Detection and analysis of UV-induced mutations in mammalian cell DNA using a lambda phage shuttle vector. Proc Natl Acad Sci U S A. 1986; 83(4):1041-4. PMC: 323006. DOI: 10.1073/pnas.83.4.1041. View

11.

Li H, Gyllensten U, Cui X, Saiki R, Erlich H, Arnheim N . Amplification and analysis of DNA sequences in single human sperm and diploid cells. Nature. 1988; 335(6189):414-7. DOI: 10.1038/335414a0. View

12.

Loeb L . Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991; 51(12):3075-9. View

13.

Gunther E, Murray N, Glazer P . High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage lambda DNA using a new E.coli lysogen. Nucleic Acids Res. 1993; 21(16):3903-4. PMC: 309930. DOI: 10.1093/nar/21.16.3903. View

14.

Prolla T, Pang Q, Alani E, Kolodner R, Liskay R . MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science. 1994; 265(5175):1091-3. DOI: 10.1126/science.8066446. View

15.

Wang G, Levy D, Seidman M, Glazer P . Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol. 1995; 15(3):1759-68. PMC: 230400. DOI: 10.1128/MCB.15.3.1759. View

16.

Li G, Modrich P . Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci U S A. 1995; 92(6):1950-4. PMC: 42400. DOI: 10.1073/pnas.92.6.1950. View

17.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J . Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-8. DOI: 10.1126/science.7761852. View

18.

Baker S, Bronner C, Zhang L, Plug A, Robatzek M, Warren G . Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell. 1995; 82(2):309-19. DOI: 10.1016/0092-8674(95)90318-6. View

19.

de Wind N, Dekker M, Berns A, Radman M, Te Riele H . Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell. 1995; 82(2):321-30. DOI: 10.1016/0092-8674(95)90319-4. View

20.

Fishel R, Kolodner R . Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev. 1995; 5(3):382-95. DOI: 10.1016/0959-437x(95)80055-7. View